Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic state coupled with a
unique CT or MR imaging appearance. Recognized in the setting of a number of complex …

Abstract Between 10%–28% of patients who receive the immuno‐suppressant cyclosporine
(CsA) experience some form of neurotoxic adverse event. Both sensorial motoric functions …

Background and Methods In some patients who are hospitalized for acute illness, we have
noted a reversible syndrome of headache, altered mental functioning, seizures, and loss of …

OBJECTIVE. Posterior reversible encephalopathy syndrome (PRES) is classically
characterized as symmetric parietooccipital edema but may occur in other distributions with …

Background Reversible posterior leukoencephalopathy syndrome (RPLS) is characterized
by neuroimaging findings of reversible vasogenic subcortical edema without infarction. The …

BACKGROUND AND PURPOSE: Although the term posterior reversible encephalopathy
syndrome (PRES) was popularized because of the typical presence of vasogenic edema in …

BACKGROUND AND PURPOSE: The recently described posterior reversible
encephalopathy syndrome (PRES) classically consists of reversible vasogenic edema in the …

BACKGROUND AND PURPOSE: Posterior reversible encephalopathy syndrome (PRES) is
typically characterized by headache, altered mental functioning, seizures, and visual loss …

Cyclosporin A (CsA) induces neurological side effects in up to 40% of patients. A reversible
posterior leukoencephalopathy syndrome is the most serious complication. Symptoms …

BACKGROUND AND PURPOSE: Hemorrhage is known to occur in posterior reversible
encephalopathy syndrome (PRES), but the characteristics have not been analyzed in detail …